Phase II Trial of Pulse Dosing of Lapatinib in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-Diagnosed Glioblastoma Multiforme
Latest Information Update: 20 May 2024
At a glance
- Drugs Lapatinib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 13 May 2024 Status changed from active, no longer recruiting to completed.
- 10 Jul 2023 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
- 10 Jul 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.